Skip to content

Preferred Stock at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$0
CorMedix logo
CorMedixCRMD
$0-100%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$0
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$0
Medline, Inc.
 logo
Medline, Inc. MDLN
$0
Charles River Laboratories logo
Charles River LaboratoriesCRL
$0

Other financials

Income statement

See full
Revenue$156.1M-29.7%
Gross profit$84.1M-37.1%
Operating income$10.5M-79.0%
Net income$6.8M-90.0%
EPS (diluted)$0.07-94.1%

Balance sheet

See full
Cash & equivalents$161.5M+5.7%
Total debt$584.6M-13.1%
Total equity$523.1M-5.4%
Total assets$1.3B-7.4%

Cash flow

See full
Operating cash flow-$33.8M-202%
CapEx$2.4M-33.3%
Free cash flow-$36.2M-145%

Valuation

See full
Market cap$411.74M+22.0%
Enterprise value$834.84M-2.6%
P/E3.6×
P/S0.6×+0.3×

Profitability

See full
Gross margin54.2%+19.0pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin20.8%

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.1×-0.1×
Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Emergent Biosolutions's preferred stock?
Emergent Biosolutions (EBS) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.